Related Experiment Videos
[Cyclic neutropenia and treatment with granulocyte colony-stimulating factor (G-CSF)]
1Academisch Medisch Centrum, Emma Kinderziekenhuis/het Kinder-AMC, Amsterdam.
Insights
Familial cyclic neutropenia (CN) is a rare blood disorder. Treatment with granulocyte-colony stimulating factor (G-CSF) significantly improved symptoms in an 18-year-old patient.
Area of Science:
- Hematology
- Genetics
- Immunology
Background:
- Familial cyclic neutropenia (CN) is a rare, inherited blood disorder characterized by periodic drops in neutrophil counts.
- Understanding the genetic basis and pathophysiology of CN is crucial for effective management.
Observation:
- A case study of an 18-year-old male with a history of familial cyclic neutropenia (CN) is presented.
- The patient experienced recurrent cervical lymphadenopathy and abscess formation, indicative of recurrent infections due to neutropenia.
Findings:
- Initiation of periodic treatment with granulocyte-colony stimulating factor (G-CSF) led to a significant reduction in symptoms and clinical improvement.
- In-vitro studies suggest CN may stem from impaired growth factor receptor signaling.
Implications:
- Granulocyte-colony stimulating factor (G-CSF) therapy is an effective treatment for managing symptomatic cyclic neutropenia.
- Further research into the molecular mechanisms of CN can lead to targeted therapies for this benign hematological disorder.
Abstract:
A patient with familial cyclic neutropenia (CN) is presented. In a son of a mother with known CN, periodic neutropenia was demonstrated a few months after birth. At 18 years of age, the boy had recurrent episodes of cervical lymphadenopathy, complicated by an abscess. Periodic treatment with granulocyte-colony stimulating factor (G-CSF) was initiated, and since then, he hardly had any symptoms and clinically showed substantial improvement. Based on in-vitro colony assays of patients with CN, it is nowadays suggested that a disturbance in growth factor receptor binding or post-receptor signal transduction is the cause of this rare benign haematological disorder.